StockData

Camp4 Therapeutics vs Praxis Precision Medicines

CAMP and PRAX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CAMP and PRAX compare

Praxis Precision Medicines is the larger company, worth 35 times as much as Camp4 Therapeutics ($9.1B against $257M).

Praxis Precision Medicines scores higher on the StockData Score (7 against 6 for Camp4 Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCAMPPRAX
Size and price
Market cap$257M$9.1B
Share price$4.09$324.76
Change, 1 year−0.97%76.9%
Change, 5 years−98.2%16.0%
Beta (5Y)2.721.65
Employees48168
StockData Score
Total score67 (better)
Valuation score00
Growth score1 (better)0
Performance score01 (better)
Health score56 (better)
Dividend score00
Valuation
P/S48.2×–
P/B2.4× (better)7.2×
FCF yield−10.3%−3.6% (better)
Fair value$2.51–
Margin of safety−63.0%–
Growth
Revenue growth (TTM)39.9%–
Profitability
Operating margin−1001%–
Net margin−2276%–
FCF margin−496%–
Return on equity−146%−44.8% (better)
Financial health
Debt / equity0.000.00
Current ratio6.4214.53 (better)
Altman Z-score1.52101.75 (better)
Piotroski F-score4 (better)3
Dividends and buybacks
Dividend yield0.00%–
Years of dividend growth0–
Shareholder yield0.00%0.00%
Ownership
Held by institutions66.5%121%
Held by insiders21.7%0.72%
Insider net buying, 12 months−$2.4M (better)−$3.6M
Short interest, % of float6.6%15.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.